Examples of using P-gp substrate in English and their translations into Swedish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Dabigatran etexilate P-gp substrate.
Other P-gp substrates for which a dose reduction may be considered include ticagrelor and dabigatran-etexilate.
Effects of afatinib on P-gp substrates.
P-gp substrates: Lomitapide inhibits P-gp in vitro, and may increase the absorption of P-gp substrates.
Effect of fidaxomicin on P-gp substrates.
Tipranavir is a P-gp substrate, a weak P-gp inhibitor
BCRP, OATP1B1, OATP1B3 and P-gp substrates.
Concomitant administration of the P-gp substrate dabigatran etexilate may result in increased dabigatran plasma concentrations.
Based on an in vitro study tigecycline is a P-gp substrate.
Lomitapide is not a P-gp substrate but does inhibit P-gp. .
Ticagrelor as well as the active metabolite are P-gp substrates.
Effect of ticagrelor on other P-gp substrates has not been studied.
The dihydrodiol metabolite and other metabolites are P-gp substrates.
Results in vivo with the P-gp substrate fexofenadine were inconclusive.
Akynzeo is unlikely to interact with medicinal products which are P-gp substrates.
Therefore, concomitant treatment with other P-gp substrates could lead to enhanced toxicity.
Isavuconazole may increase the exposure of medicinal products that are P-gp substrates.
Therefore could interact with other P-gp substrates(for example,
on dabigatran etexilate(a P-gp substrate) has not been studied.
In vitro studies have shown that paliperidone is a P-gp substrate and a weak inhibitor of P-gp at high concentrations.
and digoxin a P-gp substrate.
Therefore, concomitant treatment with other P-gp substrates could lead to.
Co-administration of digoxin, a P-gp substrate, with empagliflozin resulted in a 6% increase in AUC
digoxin(0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax.
P-gp substrate An in vitro study shows that zonisamide is a weak inhibitor of P-gp(MDR1)
Simultaneous administration of ulipristal acetate and a P-gp substrate has not been studied
does not result in clinically relevant increases in concentrations of digoxin(a P-gp substrate), with an 11% increase in plasma AUC.
Cmax for digoxin(P-gp substrate) were increased by 23% and 29% respectively, when given together due to P-gp inhibition by vandetanib.
no significant change was observed in the exposure of the P-gp substrate digoxin when administered with Viekirax and dasabuvir.
In vitro results showed for avanafil a modest potential for acting as P-gp substrate and P-gp inhibitor with digoxin as a substrate at concentrations lower than the calculated intestinal concentration.